RT Journal Article
T1 Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19
A1 Rodilla, Enrique
A1 Saura, Alberto
A1 Jiménez, Iratxe
A1 Mendizábal, Andrea
A1 Pineda-Cantero, Araceli
A1 Lorenzo-Hernández, Elizabeth
A1 Fidalgo-Montero, Maria del Pilar
A1 Fernandez López-Cuervo, Joaquín
A1 Gil-Sánchez, Ricardo
A1 Rabadán-Pejenaute, Elisa
A1 Abella-Vázquez, Lucy
A1 Giner-Galvañ, Vicente
A1 Solís-Marquínez, Marta Nataya
A1 Boixeda, Ramon
A1 de la Peña-Fernández, Andrés
A1 Carrasco-Sánchez, Francisco Javier
A1 González-Moraleja, Julio
A1 Torres-Peña, José David
A1 Guisado-Espartero, María Esther
A1 Escobar-Sevilla, Joaquín
A1 Guzmán-García, Marcos
A1 Martín-Escalante, María Dolores
A1 Martínez-González, Ángel Luis
A1 Casas-Rojo, José Manuel
A1 Gómez-Huelgas, Ricardo
K1 Hypertension
K1 COVID-19
K1 Angiotensin-converting enzyme inhibitors (ACEIs)
K1 Angiotensin II receptor blockers (ARBs)
K1 All-cause mortality
K1 Hipertensión
K1 Infecciones por coronavirus
K1 Antagonistas de receptores de angiotensina
K1 Inhibidores de la enzima convertidora de angiotensina
AB It is unclear to which extent the higher mortality associated with hypertension in the coronavirus disease (COVID-19) is due to its increased prevalence among older patients or to specific mechanisms. Cross-sectional, observational, retrospective multicenter study, analyzing 12226 patients who required hospital admission in 150 Spanish centers included in the nationwide SEMI-COVID-19 Network. We compared the clinical characteristics of survivors versus non-survivors. The mean age of the study population was 67.5 ± 16.1 years, 42.6% were women. Overall, 2630 (21.5%) subjects died. The most common comorbidity was hypertension (50.9%) followed by diabetes (19.1%), and atrial fibrillation (11.2%). Multivariate analysis showed that after adjusting for gender (males, OR: 1.5, p = 0.0001), age tertiles (second and third tertiles, OR: 2.0 and 4.7, p = 0.0001), and Charlson Comorbidity Index scores (second and third tertiles, OR: 4.7 and 8.1, p = 0.0001), hypertension was significantly predictive of all-cause mortality when this comorbidity was treated with angiotensin-converting enzyme inhibitors (ACEIs) (OR: 1.6, p = 0.002) or other than renin-angiotensin-aldosterone blockers (OR: 1.3, p = 0.001) or angiotensin II receptor blockers (ARBs) (OR: 1.2, p = 0.035). The preexisting condition of hypertension had an independent prognostic value for all-cause mortality in patients with COVID-19 who required hospitalization. ARBs showed a lower risk of lethality in hypertensive patients than other antihypertensive drugs.
PB MDPI
YR 2020
FD 2020-09-28
LK http://hdl.handle.net/10668/3366
UL http://hdl.handle.net/10668/3366
LA en
NO Rodilla E, Saura A, Jiménez I, Mendizábal A, Pineda-Cantero A, Lorenzo-Hernández E, et al. Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19. J Clin Med. 2020 Sep 28;9(10):3136.
DS RISalud
RD Apr 19, 2025